Profile
SNOA ZTS TAK HLN TEVA VTRS
Company Name Sonoma Pharmaceuticals, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $4.23M $79.21B $43.18B $42.82B $19.05B $15.58B
Employees 0.01K 14.10K 49.28K 25.41K 37.00K 32.00K
CEO Ms. Amy M. Trombly Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Mr. Brian S. Roman
Ratings
SNOA ZTS TAK HLN TEVA VTRS
Quant Rating Score 2 3 3 3 1 3
Quant Rating Sell Neutral Neutral Neutral Strong Sell Neutral
Trading
SNOA ZTS TAK HLN TEVA VTRS
Last Close $3.16 $175.56 $13.62 $9.48 $16.81 $13.05
High 52 $5.2 $199.94 $15.08 $10.69 $18.96 $13.53
Low 52 $0.13 $145.54 $12.6 $8.01 $10.44 $10.05
Price vs. 52 Week High -39.23 % -12.19 % -9.68 % -11.32 % -11.34 % -3.55 %
Price vs. 52 Week Low 2330.77 % 20.63 % 8.1 % 18.35 % 61.02 % 29.85 %
Total Return
SNOA ZTS TAK HLN TEVA VTRS
1 Month Return 0 % -9.17 % -4.95 % -6.05 % -6.35 % 10.97 %
3 Month Return 1202.56 % -4.38 % -7.72 % -3.76 % -7.99 % 11.92 %
6 Month Return 1292.07 % 0.67 % 2.56 % 11.4 % 0 % 17.89 %
9 Month Return 1900 % -5.89 % -8.1 % 14.49 % 28.62 % -1.44 %
YTD Return 1651.66 % -11.05 % -4.56 % 15.19 % 61.02 % 20.5 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
SNOA ZTS TAK HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 1.23 % 4.65 % 2.11 % - 3.68 %
Dividend Paid and Capex Coverage Ration (TTM) -52.07 % 2.1 % 1.29 % - 5.06 % 2.39 %
Dividend Per Share (TTM) - 2.16 % 0.63 % 0.16 % - 0.48 %
Payout Ratio (TTM) - 31.44 % 101.62 % - - -65.15 %
Growth
SNOA ZTS TAK HLN TEVA VTRS
Asset Growth -8.24 % -4.28 % 8.25 % -2.18 % -1.2 % -4.67 %
Gross Profit Growth 5.99 % 3.7 % -16.6 % 5.85 % 9.64 % -0.9 %
Revenue Growth -4.05 % 5.74 % 5.87 % 4.09 % 6.16 % -5.14 %
Revenue 3 Year -84.99 % 31.98 % 33.13 % 13.9 % -6.92 % -35.32 %
Revenue 5 Year -93.18 % 53.64 % 149.89 % 32.87 % -23.33 % -41.73 %
Revenue 10 Year -98.43 % 103.1 % 154.38 % 32.87 % -40.82 % -26.57 %
EBIT Growth -2.87 % 6.27 % 7.34 % 37.26 % -84.52 % -52.55 %
Net Income Growth 6.13 % 10.88 % -54.56 % -1.04 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share 77 % 47.55 % -61.74 % -8.67 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share 95.83 % 71.94 % 62.27 % 59.66 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share -102.18 % 404.24 % 36.33 % 59.66 % -133.42 % -97.12 %
Operating Income Growth -2.87 % 6.27 % 7.34 % 37.26 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 61.02 % 23.06 % -34.47 % -16.48 % -13.96 % -5.18 %
Operating 3 Year CFG 84.41 % 14.12 % -36.76 % 22.08 % 10.09 % 13.84 %
Operating 5 Year CFG 97.92 % 37.69 % 139.61 % 118.54 % -48.98 % -48.37 %
Operating 10 Year CFG 99.17 % 274.61 % 335.67 % 118.54 % -67.94 % -16.8 %
EPS Growth 65.13 % 12.64 % -54.92 % - 76.42 % -97.08 %
EPS Diluted Growth 65.13 % 12.92 % -54.86 % - 76.42 % -97.08 %
Book Value Per Share -71.27 % 15.25 % 13.54 % 1.35 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share -74.87 % 36.7 % 40.38 % -36.6 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share -94.05 % 139.55 % 73.27 % -39.41 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share -99.14 % 476.36 % 197.1 % -39.41 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % 1.95 % -85.58 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % 1.19 % -83.69 % - -
Dividend 5 Year Growth Per Share - 198.29 % 146.94 % -66.42 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % 103.93 % -66.42 % -100 % -
Debt Growth -28.39 % -15.91 % 24.67 % -9.43 % -6.53 % -5.93 %
Free Cash Flow Growth 62.39 % 22.25 % -53.54 % -20.06 % -19.19 % -7.35 %
Updated On 31 Mar 2024 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
SNOA ZTS TAK HLN TEVA VTRS
Gross Profit Margin TTM 38.52 % 68.87 % 62.47 % 59.91 % 49.87 % 40.26 %
Return on Assets TTM -26.93 % 16.93 % 1.99 % 3.26 % -2.38 % -1.97 %
Return on Equity TTM -63.67 % 47.99 % 4.04 % 6.54 % -14.58 % -4.43 %
Return on Capital Employed TTM -41.21 % 26.64 % 5.27 % 7.25 % 7.66 % -0.71 %
Net Income Per EBT TTM 98.5 % 79.65 % 109.03 % 65.38 % 175.89 % 92.81 %
EBT Per Ebit TTM 87.51 % 90.51 % 41.38 % 82.66 % -26.34 % 359.67 %
EBIT Per Revenue TTM -31.56 % 36.83 % 14.14 % 17.88 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM -1841.46 % 44.8 % 17.01 % - 13 % 13.05 %
Receivables Turnover TTM 4.29 6.49 6.3 5.27 4.85 4.04
Payables Turnover TTM 10.82 7.05 4.13 1.25 3.55 7.23
Inventory Turnover TTM 2.94 1.18 1.41 3.09 2.13 2.2
Fixed Asset Turnover TTM 3248.68 % 259.93 % 240.84 % 604.62 % 278.05 % 561.67 %
Asset Turnover TTM 98.99 % 63.75 % 31.2 % 33.71 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM -1.46 6.5 545.34 - 2.18 1.93
Free Cash Flow Per Share TTM -1.49 5.1 309.43 - 1.75 1.6
Cash Per Share TTM 394.39 % 378.45 % 57513.46 % 5.72 % 292.94 % 157.41 %
Operating Cash Flow Sales Ratio TTM -11.15 % 32.18 % 18.9 % - 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 101.92 % 78.37 % 56.74 % - 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM -1841.46 % 44.8 % 17.01 % - 13 % 13.05 %
Price To Free Cash Flows Ratio TTM -2.75 34.32 13.8 - 9.62 8.14
Price To Operating Cash Flows Ratio TTM -2.16 27 3.89 - 7.72 6.77
Price Cash Flow Ratio TTM -2.16 27 3.89 - 7.72 6.77
Income Statement (TTM)
SNOA ZTS TAK HLN TEVA VTRS
Revenue $0.01B $8.54B $4263.76B $11.3B $15.85B $15.43B
Gross Profit $0B $5.83B $2321.31B $6.96B $7.65B $6.44B
Gross Profit Ratio 37.26% 68.28% 54.44% 61.6% 48.25% 41.74%
EBITDA $-0B $3.69B $900.33B $2.35B $4.33B $3.52B
Net Income $-0B $2.34B $144.07B $1.05B $-0.56B $0.05B
EPS Diluted -10.64 5.07 91.16 0.11 -0.5 0.05
Balance Sheet (MRQ)
SNOA ZTS TAK HLN TEVA VTRS
Long Term Debt $0B $6.75B $5029.93B $8.95B $18.48B $16.35B
Total Liabilities $0.01B $9.3B $7834.79B $17.33B $35.35B $27.22B
Total Equity $0.01B $4.99B $7274.01B $16.73B $8.13B $20.47B
Total Investments $0B $0.02B $683.22B $0.07B $0.01B $1.33B
Total Debt $0B $6.76B $5463.39B $9.46B $20.15B $18.37B
Total Assets $0.01B $14.29B $15108.79B $34.06B $43.48B $47.69B
Cash Flow Statement (TTM)
SNOA ZTS TAK HLN TEVA VTRS
Net Income $-0B $2.34B $144.07B $1.05B $-0.62B $0.05B
Inventory $0B $-0.36B $-115.74B $-0.13B $0B $-0.61B
Dividends Paid $0B $-0.69B $-287.19B $-0.39B $0B $-0.58B
Operating Cash Flow $-0B $2.35B $640.32B $1.72B $1.37B $2.8B
Capital Expenditure $-0B $-0.73B $-480.73B $-0.34B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.24
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.37
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 12.42
ALVOW Alvotech 3.4
AMPH Amphastar Pharmaceuticals, Inc. 44.09
AMRX Amneal Pharmaceuticals, Inc. 8.41
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 55.1
AQST Aquestive Therapeutics, Inc. 4.735
ASRT Assertio Holdings, Inc. 0.95
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 10.75
AYTU Aytu BioPharma, Inc. 1.49
ETFs With Exposure to SNOA
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 130.17
VXF Vanguard Extended Market Index Fund 0 196.7
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 149.17
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 149.17
VEMPX Vanguard Extended Market Index InstlPlus 0 368.12
Unlock